Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

High TP53 Mutation Load Predicts Primary Refractory Mantle Cell Lymphoma

Aleš Obr, MD PhD, Pavel Klener, Jr., Eva Kriegova, Dr, assoc prof, Zuzana Zemanova, PhD, Helena Urbankova, MSc, PhD, Andrea Jirkuvova, MD, Anna Petrackova, MSc, Barbora Cudova, Lenka Sedlarikova, MSc, VIT K Prochazka, MD, Tomas Papajik, MD prof, Marek Trneny, MD prof

Blood (2019) 134 (Supplement_1): 3995.

https://doi.org/10.1182/blood-2019-123812

Published: 2019

Journal Articles

Randomized Open-Labeled Academic Trial Comparing Standard AZA Therapy with Combination of G-CSF with AZA in High Risk MDS Patients - Interim Analysis

Anna Jonasova, MD PhD, Lubomir Minarik, MD, Vojtech Kulvait, PhD, Michal Pesta, PhD, Adel Schaffartzikova, MD, Galina Kislik, PhD, Nina Dusilkova, MD, Zuzana Zemanova, PhD, Tomas Stopka, MD PhD

Blood (2019) 134 (Supplement_1): 1729.

https://doi.org/10.1182/blood-2019-124274

Published: 2019

Journal Articles

RUNX1 Mutation Accompanied with Dysregulated Cellular Senescence in Lower-Risk Myelodysplastic Syndrome Patients Is Associated with Disease Progression

Monika Hruba, Jitka Vesela, Hana Votavova, PhD, Michaela Dostalova Merkerova, PhD MSc, David Kundrat, Katarina Szikszai, PhD, Marie Lauermanova, MD, Zuzana Zemanova, PhD, Anna Jonasova, MD PhD, Jaroslav Cermak, MD PhD, Monika Belickova, PhD

Blood (2019) 134 (Supplement_1): 4230.

https://doi.org/10.1182/blood-2019-131150

Published: 2019

Journal Articles

Co-Targeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Refractory Mantle Cell Lymphoma with Complex Karyotype Changes

Pavel Klener, Jr., Marek Trněný, Ladislav Andera, MSc, PhD, Zuzana Nahacka, MSc, Magdalena Klanova, MD PhD, Jana Karolova, MD, Michael Svaton, MD, Ondrej Havranek, MDPhD, Jan Soukup, MD, Zuzana Zemanova, PhD, Diana Tuskova, MD, Eva Pokorna, Kristina Forsterova, MSc, PhD, Petra Vockova, MD, Eva Fronkova, MD PhD, Dana Prukova, Ing, PhD

Blood (2018) 132 (Supplement 1): 42.

https://doi.org/10.1182/blood-2018-99-112437

Published: 2018

Journal Articles

Chromothripsis in High-Risk Myelodysplastic Syndromes: Incidence, Genetic Features, Clinical Implications, and Impact on Survival of Patients Treated with Azacytidine (Data from Czech MDS Group)

Zuzana Zemanova, PhD, Kyra Michalova, PhD, Karla Svobodova, Jana Brezinova, Halka Lhotska, PhD, Libuse Lizcova, PhD, Iveta Sarova, PhD, Silvia Izakova, Lucie Hodanova, PhD, Denisa Vesela, Sarka Ransdorfova, Monika Belickova, PhD, Jitka Vesela, MSc, Helena Polackova, Magda Siskova, MD, Radana Neuwirtova, MD PhD, Jaroslav Cermak, MD PhD, Tomas Stopka, MD PhD, Anna Jonasova, MD

Blood (2018) 132 (Supplement 1): 1815.

https://doi.org/10.1182/blood-2018-99-114151

Published: 2018

Journal Articles

Importance of Transcription Factor Nrf2 for Cereblon Expression and Clinical Response to Combination of Lenalidomide and Erythropoietin in Lower-Risk Myelodysplastic Syndromes

Radka Bokorová, MSc, Jaroslav Polak, MSc, Anna Jonasova, MD, Radana Neuwirtova, MD PhD, Marie Lauermannova, MD, Jaroslav Cermak, MD PhD, Marketa Stastna, MD PhD, Cyril Salek, Dana Mikulenkova, MD, Zuzana Zemanova, PhD, Jana Brezinova, Kyra Michalova, PhD, Denisa Myslivcova, PhD, Ota Fuchs, PhD

Blood (2018) 132 (Supplement 1): 5507.

https://doi.org/10.1182/blood-2018-99-115803

Published: 2018

Journal Articles

Mutations in RUNX1 and TP53 Genes Predict Progression in Patients with Lower-Risk Myelodysplastic Syndrome

Monika Hruba, MSc, Jitka Vesela, MSc, Hana Votavova, PhD, Michaela Dostalova Merkerova, PhD MSc, Katarina Szikszai, PhD, Marie Lauermannova, MD, Zuzana Zemanova, PhD, Anna Jonasova, MD, Jaroslav Cermak, MD PhD, Monika Belickova, PhD

Blood (2018) 132 (Supplement 1): 5519.

https://doi.org/10.1182/blood-2018-99-118048

Published: 2018

Journal Articles

Measurement of Increase in Cereblon mRNA Level after Addition of Erythropoietin to Lenalidomide May Predict a Clinical Response to Combination of Both the Drugs in Patients with Lower-Risk Myelodysplastic Syndromes

Radka Bokorová, Jaroslav Polak, MSc, Arnost Kostecka, Anna Jonasova, MD PhD, Radana Neuwirtova, MD PhD, Tomas Stopka, MD PhD Assoc Proff, Marie Lauermannova, Jaroslav Cermak, MD PhD, Dana Mikulenkova, Zuzana Zemanova, PhD, Jana Brezinova, PhD, Ota Fuchs, PhD

Blood (2017) 130 (Supplement 1): 5295.

https://doi.org/10.1182/blood.V130.Suppl_1.5295.5295

Published: 2017

Journal Articles

Clonal Architecture of MDS Somatic Mutations Dynamically Changes during Azacitidine Therapy and Has Very Limited Potential to Predict Patient Outcome

Kamila Polgarova, MD, Vojtech Kulvait, MSc, Karina Vargova, PhD, Lubomir Minarik, MD, Nina Dusilkova, MD, Zuzana Zemanova, PhD, Anna Jonasova, MD PhD, Tomas Stopka, MD PhD

Blood (2016) 128 (22): 4294.

https://doi.org/10.1182/blood.V128.22.4294.4294

Published: 2016

Journal Articles

Frequency and Clinical Impact of Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5q)

Zuzana Zemanova, PhD, Kyra Michalova, PhD, Jana Brezinova, PhD, Karla Svobodova, Halka Lhotska, Iveta Sarova, PhD, Libuse Lizcova, PhD, Silvia Izakova, Sarka Ransdorfova, PhD, Lenka Pavlistova, PhD, Adela Berkova, PhD, Karolina Skipalova, Monika Belickova, PhD, Magda Siskova, MD, Radana Neuwirtova, MD PhD, Jaroslav Cermak, MD PhD, Tomas Stopka, MD PhD, Anna Jonasova, MD PhD

Blood (2016) 128 (22): 1982.

https://doi.org/10.1182/blood.V128.22.1982.1982

Published: 2016

Journal Articles

Why Patients with 5q- Syndrome Have Thrombocythemia?

Vit Campr, MD PhD, Jan Stritesky, MD PhD, Ota Fuchs, PhD, Anna Jonasova, MD PhD, Zuzana Zemanova, PhD, Radana Neuwirtova, MD PhD

Blood (2016) 128 (22): 5533.

https://doi.org/10.1182/blood.V128.22.5533.5533

Published: 2016

Journal Articles

Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/ MLL -Rearranged AML: Results from an International Retrospective Study

Blood (2010) 116 (21): 762.

https://doi.org/10.1182/blood.V116.21.762.762

Published: 2010

Journal Articles

B Precursor ALL Subset with Aberrant CD2 Expression and a Specific Predisposition to Early Monocytic Transdifferentiation

Ester Mejstrikova, MD, PhD, Lucie Slamova, MD, Eva Fronkova, MD, PhD, Jan Zuna, MD, PhD, Jean-Pierre Bourquin, MD, PhD, Elena Vodickova, MD, Katerina Muzikova, Zuzana Zemanova, PhD, Vendula Pelkova, Frederik Van Delft, PhD, Tomas Kalina, MD, PhD, Karel Fiser, PhD, Petr Smisek, MD, Jan Trka, MD, PhD, Jan Stary, MD, DrSc, Ondrej Hrusak, MD, PhD

Blood (2010) 116 (21): 1708.

https://doi.org/10.1182/blood.V116.21.1708.1708

Published: 2010

NARROW

High TP53 Mutation Load Predicts Primary Refractory Mantle Cell Lymphoma

Randomized Open-Labeled Academic Trial Comparing Standard AZA Therapy with Combination of G-CSF with AZA in High Risk MDS Patients - Interim Analysis

RUNX1 Mutation Accompanied with Dysregulated Cellular Senescence in Lower-Risk Myelodysplastic Syndrome Patients Is Associated with Disease Progression

Co-Targeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Refractory Mantle Cell Lymphoma with Complex Karyotype Changes

Chromothripsis in High-Risk Myelodysplastic Syndromes: Incidence, Genetic Features, Clinical Implications, and Impact on Survival of Patients Treated with Azacytidine (Data from Czech MDS Group)

Importance of Transcription Factor Nrf2 for Cereblon Expression and Clinical Response to Combination of Lenalidomide and Erythropoietin in Lower-Risk Myelodysplastic Syndromes

Mutations in RUNX1 and TP53 Genes Predict Progression in Patients with Lower-Risk Myelodysplastic Syndrome

Measurement of Increase in Cereblon mRNA Level after Addition of Erythropoietin to Lenalidomide May Predict a Clinical Response to Combination of Both the Drugs in Patients with Lower-Risk Myelodysplastic Syndromes

Clonal Architecture of MDS Somatic Mutations Dynamically Changes during Azacitidine Therapy and Has Very Limited Potential to Predict Patient Outcome

Frequency and Clinical Impact of Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5q)

Why Patients with 5q- Syndrome Have Thrombocythemia?

Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/ MLL -Rearranged AML: Results from an International Retrospective Study

B Precursor ALL Subset with Aberrant CD2 Expression and a Specific Predisposition to Early Monocytic Transdifferentiation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only